PA-STRATUS-MATERIALS
25.6.2024 15:02:03 CEST | Business Wire | Press release
Stratus Materials Inc., a company focused on the development and commercialization of advanced cathode active materials (CAMs) for lithium-ion batteries, today announced that its first-generation LXMO CAM material has achieved a significant milestone associated with cycling durability in electric vehicle applications.
This month, LXMO-containing pouch cells surpassed 1,000 full depth-of-discharge cycles while maintaining greater than 80% of their initial capacity, a common goal across the EV battery industry. The 3rd party-built cells used standard cell and electrode designs, employing a natural graphite anode and an electrolyte of standard industry components, to work in conjunction with the Stratus cathode material. The cells in the test group maintained 82-86% of their initial capacity and are projected to exceed 1,200 cycles before reaching 80% of their initial capacities. At the same 1,000-cycle point, the average discharge voltage of the cells maintained approximately 97%, dropping only 0.1 V from their initial values. The excellent capacity and voltage stability of the cells surpass the energy retention of many commercial materials in use today.
Jay Whitacre, CEO & CTO of Stratus Materials (and Professor at Carnegie Mellon University), said: “These cells have been cycling for the last 10 months and clearly demonstrate that our proprietary materials are able to meet EV industry durability needs. To our knowledge this is the first time such minimal loss in cell voltage has been documented for this class of materials. The Stratus team looks forward to building upon these strong technical results as we improve, commercialize, and scale production in the coming quarters.”
Stratus products are in the lithium-rich, manganese-rich (LMR) category of cathode active materials. LMR cathodes have garnered significant interest in the Li-ion battery and EV industries due to several highly promising attributes including high energy density, low cost, and high safety. However, despite being in development around the world for over two decades, LMRs have not yet been commercially deployed because of several persistent technical challenges – primarily the voltage and capacity instability issues that Stratus Materials has largely overcome, as demonstrated by its latest results. With its continued technological progress, Stratus Materials is focused on enabling the first fully functional, LMR-class CAMs that are suitable for full-scale, commercial use.
Scott Pearson, President & CCO, added: “We are thrilled to show that our first-generation LXMO material can exceed this EV cell durability target while also delivering a set of highly compelling advantages versus incumbent CAMs. We expect that this proof point will be one of many that we will be offering to our industry partners and customers.”
Stratus is currently producing materials on its existing pre-pilot production line in Pittsburgh, Pennsylvania and has ongoing sampling efforts underway with many of the leading companies in the EV and EV battery industries. As previously announced, the company will be increasing its production capabilities from pre-pilot to pilot scale later in 2024.
ABOUT STRATUS MATERIALS
Stratus Materials (www.stratusmaterials.com) is a U.S. based company focused on the development and commercialization of next-generation cathode active materials (CAMs) for lithium-ion batteries. Our mission is to disrupt the CAM supply chain by offering materials with a game-changing combination of performance, safety, and cost. Stratus is primarily focusing its cobalt-free LXMOTM cathode products on light- and medium-duty electric vehicles and other applications with similar requirements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625022288/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
